258 related articles for article (PubMed ID: 31790459)
1. Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Ryu JY; Min KL; Chang MJ
PLoS One; 2019; 14(12):e0225599. PubMed ID: 31790459
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
3. Association of plasma levetiracetam concentration, MGMT methylation and sex with survival of chemoradiotherapy-treated glioblastoma patients.
Cucchiara F; Luci G; Giannini N; Giorgi FS; Orlandi P; Banchi M; Di Paolo A; Pasqualetti F; Danesi R; Bocci G
Pharmacol Res; 2022 Jul; 181():106290. PubMed ID: 35680010
[TBL] [Abstract][Full Text] [Related]
4. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
5. Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Tinchon A; Oberndorfer S; Marosi C; Gleiss A; Geroldinger A; Sax C; Sherif C; Moser W; Grisold W
J Neurol; 2015 Jan; 262(1):179-86. PubMed ID: 25359262
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
7. Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy.
Roh TH; Moon JH; Park HH; Kim EH; Hong CK; Kim SH; Kang SG; Chang JH
Sci Rep; 2020 Jul; 10(1):10783. PubMed ID: 32612203
[TBL] [Abstract][Full Text] [Related]
8. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
9. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
10. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
13. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.
Cardona AF; Rojas L; Wills B; Bernal L; Ruiz-Patiño A; Arrieta O; Hakim EJ; Hakim F; Mejía JA; Useche N; Bermúdez S; Carranza H; Vargas C; Otero J; Mayor LC; Ortíz LD; Franco S; Ortíz C; Gil-Gil M; Balaña C; Zatarain-Barrón ZL
J Neurooncol; 2018 Jan; 136(2):363-371. PubMed ID: 29177594
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care and outcomes of chemoradiation versus radiation alone for MGMT promoter unmethylated glioblastoma.
Lee A; Malakhov N; Sheth N; Wang A; Han P; Schreiber D
Clin Neurol Neurosurg; 2018 Jul; 170():127-131. PubMed ID: 29777945
[TBL] [Abstract][Full Text] [Related]
17. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
Guler OC; Yıldırım BA; Önal C; Topkan E
Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
[TBL] [Abstract][Full Text] [Related]
18. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
20. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]